Echocardiography in Young Athletes

Sports Cardiology

Echocardiography in Young Athletes. Introduction

Sudden cardiac death (SCD) in young athletes, although rare, is one of the most tragic events in sports medicine. Incidence rates range between 1/14,000 and 1/100,000 per year, with a risk 6 to 8 times higher than in non-athletes of the same age. Given this reality, pre-participation cardiovascular screening (PPCS) has become an effective strategy to identify individuals at risk. In this context, transthoracic echocardiography (TTE) stands out as a fundamental tool, not only as a test complementary to the ECG but also as a first-line test in certain scenarios.


Echocardiography in Young Athletes. Clinical reasoning

The 2025 guidelines from the British Society of Echocardiography (BSE) y Cardiac Risk in the Young (CRY) stress that TTE has a direct diagnostic capability for many of the structural conditions responsible for SCD in young athletes:

  • Hypertrophic cardiomyopathy (HCM)
  • Dilated cardiomyopathy (DCM)
  • Arrhythmogenic cardiomyopathy (ACM)
  • Congenital coronary artery anomalies
  • Ventricular fibrosis and dysplasia
  • Myocarditis and valve disease

Recent UK data on 748 athletes who died showed that 42% of the men and 30% of the women had conditions that would have been detectable by echocardiography.


Comparison with the ECG: sensitivity and limitations

The standard European protocol for cardiac screening includes:

  1. Structured medical history
  2. Physical examination
  3. 12-lead ECG
  4. TTE (only if abnormalities are found)

Although the ECG is highly sensitive for some cardiomyopathies and channelopathies, up to 16% of sudden deaths are associated with structural heart disease with a normal ECG, which justifies including echocardiography as a screening tool even in asymptomatic athletes with no obvious electrical abnormalities.

The additional diagnostic yield of TTE in screening studies ranges between 1.2% y 4.5%.


Echocardiography as a primary screening tool

Some sports organisations, especially at professional level, have adopted TTE as a baseline study, even without clinical or ECG abnormalities, for several reasons:

  • It helps rule out congenital heart disease and silent valve disease.
  • It accurately assesses ventricular geometry, wall thickness, volumes and systolic and diastolic function.
  • It identifies early signs of post-viral myocarditis, especially relevant after the SARS-CoV-2 pandemic.

TTE is also essential to correctly interpret the physiological adaptations of the "athlete's heart" and distinguish them from early disease.


Echocardiography and "Return to Play" after COVID or myocarditis

One of the most relevant contributions today is the role of TTE in returning to sport after a viral infection. The prevalence of post-COVID myocarditis in symptomatic athletes ranges between 0.2% y 4%, and TTE allows you to:

  • Confirm normal ventricular function
  • Exclude pericardial effusion or wall thickening
  • Detect subclinical dysfunction using global longitudinal strain (GLS)

TTE is recommended in athletes with cardiac symptoms after infection before they resume competitive training.


Physiological vs pathological adaptations: the interpretive challenge

Intense training produces a series of physiological cardiac adaptations that can mimic disease. These include:

  • Eccentric left ventricular hypertrophy (physiological LVH)
  • Bilateral atrial enlargement
  • Structural adaptation of the right ventricle

The echocardiographer must analyse these changes based on:

  • Type of training (endurance vs strength)
  • Training load (measured in METs x hours/week)
  • The athlete's sex, age, ethnicity and height

Key example: GLS ≤ −15% or LVEF <47% at rest may indicate disease, but borderline values (GLS −16%, LVEF 48–54%) in dilated chambers may be physiological and require further assessment with SE or cMRI.


Key functional parameters in athletes

The following echocardiographic values have proved useful in assessing athletes:

ParameterTypical value in athletesClinical interpretation
LVEF (%)47–65≤47% indicates possible disease
GLS (%)−17% a −20%≤−15% suggests myocardial dysfunction
TAPSE (mm)>17≤16 may be pathological in the RV context
RVFAC (%)>32<30% suggests RV dysfunction
RV:LV ratio<0.9>0.9 may suggest pathological remodelling

When to recommend further tests

TTE may point to the need for advanced tests if any of the following are found:

  • Concentric or asymmetric ventricular hypertrophy
  • Disproportionate ventricular dilatation
  • Reduced longitudinal function (GLS, S', RV strain)
  • Abnormal valve morphology (e.g. SAM, bicuspid aortic valve)
  • Anomalous coronary ostia or aberrant flow

Conclusion

Echocardiography, far from being just a secondary tool, should be considered a primary, essential instrument in the cardiovascular screening of young athletes. Its ability to detect structural heart disease early, put physiological adaptations in context and provide objective criteria during "return to play" justifies its systematic inclusion in preventive protocols, especially in at-risk or elite populations.

Combining it with the ECG and other advanced techniques (strain, SE, 3DE) significantly raises the diagnostic quality of screening, reduces the risk of sudden death and improves the safety of sport in young people.

References:

https://echo.biomedcentral.com/articles/10.1186/s44156-025-00069-0

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *